Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Milvexian reversal study with 4F-PCC in healthy volunteers
NL-OMON54179Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2020
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of milvexian and prothrombin complex concentrate, human in thromboembolism (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Reversal of anticoagulant effects measured by coagulation parameters. Started Aug 2020; status: active, not recruiting.
02
Drugs
milvexianprothrombin complex concentrate, human
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NL-OMON54179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54179.